Dorsey Brian
SEC insider (Form 3/4/5 filer). CIK 0001380762. Chief Operating Officer at ARS Pharmaceuticals, Inc. (SPRY). 8 reported Form 4/5 transactions since Sep 2024; latest on Jan 2, 2026. Located in SAN DIEGO, CA.
Companies Dorsey Brian has filed insider reports for
- ARS Pharmaceuticals, Inc. (SPRY): Officer, Chief Operating Officer
Dorsey Brian
CIK: 0001380762
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ARS Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jan 2, 2026SPRY
ARS Pharmaceuticals, Inc.
AwardDirectStock option (right to buy)
240K shares- - Nov 13, 2025SPRY
ARS Pharmaceuticals, Inc.
SaleDirect21.8K shares at avg. $8.71$190K - Nov 13, 2025SPRY
ARS Pharmaceuticals, Inc.
ExerciseDirect21.8K shares at avg. $0.64$14K - Jan 2, 2025SPRY
ARS Pharmaceuticals, Inc.
AwardDirectStock option (right to buy)
261.9K shares- - Dec 12, 2024SPRY
ARS Pharmaceuticals, Inc.
ExerciseDirect25K shares at avg. $0.64$16K - Dec 12, 2024SPRY
ARS Pharmaceuticals, Inc.
SaleDirect25K shares at avg. $12.30$307K - Dec 11, 2024SPRY
ARS Pharmaceuticals, Inc.
SaleDirect15K shares at avg. $12.43$186K - Dec 11, 2024SPRY
ARS Pharmaceuticals, Inc.
ExerciseDirect15K shares at avg. $0.64$10K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | SPRY ARS Pharmaceuticals, Inc. | Award Stock option (right to buy) | 240,000 | - | - | Direct |
| Nov 13, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale | 21,828 | $8.71 | $190,050 | Direct |
| Nov 13, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise | 21,828 | $0.64 | $13,970 | Direct |
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award Stock option (right to buy) | 261,900 | - | - | Direct |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise | 25,000 | $0.64 | $16,000 | Direct |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale | 25,000 | $12.30 | $307,433 | Direct |
| Dec 11, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale | 15,000 | $12.43 | $186,426 | Direct |
| Dec 11, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise | 15,000 | $0.64 | $9,600 | Direct |
1-8 of 8 transactions